Interferon-free therapy of hepatitis C during wait list and post-transplant risk of hepatocellular carcinoma recurrence

Maria Francesca Donato¹, Federica Invernizzi², Giorgio Rossi³, Massimo Iavarone²

Affiliations

¹ "A. M. and A. Migliavacca" Center for Liver Disease, Division of Gastroenterology and Hepatology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Italy. Electronic address: francesca.donato@policlinico.mi.it.
² "A. M. and A. Migliavacca" Center for Liver Disease, Division of Gastroenterology and Hepatology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Italy.
³ Division of General Surgery and Liver Transplantation, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Italy.

PMID: 28803950
DOI: 10.1016/j.jhep.2017.07.026

Comment

Interferon-free therapy of hepatitis C during wait list and post-transplant risk of hepatocellular carcinoma recurrence

Maria Francesca Donato et al. J Hepatol. 2017 Dec.

. 2017 Dec;67(6):1355-1356.

doi: 10.1016/j.jhep.2017.07.026. Epub 2017 Aug 10.

Authors

Maria Francesca Donato¹, Federica Invernizzi², Giorgio Rossi³, Massimo Iavarone²

Affiliations

¹ "A. M. and A. Migliavacca" Center for Liver Disease, Division of Gastroenterology and Hepatology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Italy. Electronic address: francesca.donato@policlinico.mi.it.
² "A. M. and A. Migliavacca" Center for Liver Disease, Division of Gastroenterology and Hepatology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Italy.
³ Division of General Surgery and Liver Transplantation, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Italy.

PMID: 28803950
DOI: 10.1016/j.jhep.2017.07.026

No abstract available

PubMed Disclaimer

Comment in

Reply to: "Interferon-free therapy of hepatitis C during wait list and post transplant risk of hepatocellular carcinoma recurrence".
Yang JD, Leise MD. Yang JD, et al. J Hepatol. 2017 Dec;67(6):1357. doi: 10.1016/j.jhep.2017.08.001. Epub 2017 Aug 9. J Hepatol. 2017. PMID: 28800877 No abstract available.

Comment on

Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma.
Yang JD, Aqel BA, Pungpapong S, Gores GJ, Roberts LR, Leise MD. Yang JD, et al. J Hepatol. 2016 Oct;65(4):859-860. doi: 10.1016/j.jhep.2016.06.023. Epub 2016 Jul 5. J Hepatol. 2016. PMID: 27392425 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Interferon-free therapy of hepatitis C during wait list and post-transplant risk of hepatocellular carcinoma recurrence

Affiliations

Interferon-free therapy of hepatitis C during wait list and post-transplant risk of hepatocellular carcinoma recurrence

Authors

Affiliations

Comment in

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical